Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.

Autor:	Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Deitchman AN; Department of Clinical Pharmacy, University of California, San Francisco, CA, USA., Torres L; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Iyer NS; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Munter SE; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Nixon CC; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Donatelli J; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Thanh C; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Takahashi S; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Hakim J; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Turcios K; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Janson O; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Hoh R; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Tai V; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Hernandez Y; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Fehrman EA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Spinelli MA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Gandhi M; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Trinh L; Monogram Biosciences, Inc., South San Francisco, CA, USA., Wrin T; Monogram Biosciences, Inc., South San Francisco, CA, USA., Petropoulos CJ; Monogram Biosciences, Inc., South San Francisco, CA, USA., Aweeka FT; Department of Clinical Pharmacy, University of California, San Francisco, CA, USA., Rodriguez-Barraquer I; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA., Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA., Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA., Greenhouse B; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA; Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA., Rutishauser RL; Monogram Biosciences, Inc., South San Francisco, CA, USA., Henrich TJ; Monogram Biosciences, Inc., South San Francisco, CA, USA. Electronic address: timothy.henrich@ucsf.edu.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2021 Aug 10; Vol. 36 (6), pp. 109518. Date of Electronic Publication: 2021 Aug 06.
DOI:	10.1016/j.celrep.2021.109518
Abstrakt:	We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses, soluble markers of inflammation, and antibody levels and neutralization capacity longitudinally in 70 individuals with PCR-confirmed SARS-CoV-2 infection. Participants represent a spectrum of illness and recovery, including some with persistent viral shedding in saliva and many experiencing post-acute sequelae of SARS-CoV-2 infection (PASC). T cell responses remain stable for up to 9 months. Whereas the magnitude of early CD4 + T cell immune responses correlates with severity of initial infection, pre-existing lung disease is independently associated with higher long-term SARS-CoV-2-specific CD8 + T cell responses. Among participants with PASC 4 months following coronavirus disease 2019 (COVID-19) symptom onset, we observe a lower frequency of CD8 + T cells expressing CD107a, a marker of degranulation, in response to Nucleocapsid (N) peptide pool stimulation, and a more rapid decline in the frequency of N-specific interferon-γ-producing CD8 + T cells. Neutralizing antibody levels strongly correlate with SARS-CoV-2-specific CD4 + T cell responses. Competing Interests: Declaration of interests L.T., T.W., and C.J.P. are employees of Monogram Biosciences, a division of LabCorp. T.J.H. reports grants from Merck, Gilead Biosciences, and Bristol-Myers Squibb outside the submitted work. (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu